Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

Siraj M Ali; R Kathy Alpaugh; Jamie K Buell; Philip J Stephens; Jian Qin Michael Yu; Hong Wu; Christine N Hiemstra; Vincent A Miller; Doron Lipson; Gary A Palmer; Jeffrey S Ross; Massimo Cristofanilli

doi:10.1016/j.clbc.2013.09.010

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

Siraj M Ali, R Kathy Alpaugh, Jamie K Buell, Philip J Stephens, Jian Qin Michael Yu, Hong Wu, Christine N Hiemstra, Vincent A Miller, Doron Lipson, Gary A Palmer, Jeffrey S Ross, Massimo Cristofanilli

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Original language	English
Pages (from-to)	e14-6
Journal	Clinical Breast Cancer
Volume	14
Issue number	1
DOIs	https://doi.org/10.1016/j.clbc.2013.09.010
State	Published - Jan 2014

Keywords

ErbB Receptors/antagonists & inhibitors
Erlotinib Hydrochloride
Female
Humans
Inflammatory Breast Neoplasms/drug therapy
Middle Aged
Mutation
Protein Kinase Inhibitors/therapeutic use
Quinazolines/therapeutic use

Access to Document

10.1016/j.clbc.2013.09.010

Cite this

Ali, S. M., Alpaugh, R. K., Buell, J. K., Stephens, P. J., Yu, J. Q. M., Wu, H., Hiemstra, C. N., Miller, V. A., Lipson, D., Palmer, G. A., Ross, J. S., & Cristofanilli, M. (2014). Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clinical Breast Cancer, 14(1), e14-6. https://doi.org/10.1016/j.clbc.2013.09.010

@article{ee4c2f9dae304d379165581d8cb563d2,

title = "Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib",

keywords = "ErbB Receptors/antagonists & inhibitors, Erlotinib Hydrochloride, Female, Humans, Inflammatory Breast Neoplasms/drug therapy, Middle Aged, Mutation, Protein Kinase Inhibitors/therapeutic use, Quinazolines/therapeutic use",

author = "Ali, {Siraj M} and Alpaugh, {R Kathy} and Buell, {Jamie K} and Stephens, {Philip J} and Yu, {Jian Qin Michael} and Hong Wu and Hiemstra, {Christine N} and Miller, {Vincent A} and Doron Lipson and Palmer, {Gary A} and Ross, {Jeffrey S} and Massimo Cristofanilli",

year = "2014",

month = jan,

doi = "10.1016/j.clbc.2013.09.010",

language = "English",

volume = "14",

pages = "e14--6",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

AU - Ali, Siraj M

AU - Alpaugh, R Kathy

AU - Buell, Jamie K

AU - Stephens, Philip J

AU - Yu, Jian Qin Michael

AU - Wu, Hong

AU - Hiemstra, Christine N

AU - Miller, Vincent A

AU - Lipson, Doron

AU - Palmer, Gary A

AU - Ross, Jeffrey S

AU - Cristofanilli, Massimo

PY - 2014/1

Y1 - 2014/1

KW - ErbB Receptors/antagonists & inhibitors

KW - Erlotinib Hydrochloride

KW - Female

KW - Humans

KW - Inflammatory Breast Neoplasms/drug therapy

KW - Middle Aged

KW - Mutation

KW - Protein Kinase Inhibitors/therapeutic use

KW - Quinazolines/therapeutic use

U2 - 10.1016/j.clbc.2013.09.010

DO - 10.1016/j.clbc.2013.09.010

M3 - Article

C2 - 24201163

SN - 1526-8209

VL - 14

SP - e14-6

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 1

ER -

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

Keywords

Access to Document

Fingerprint

Cite this